You are here: Home
Last month June 2018 Next month
week 22 1 2 3
week 23 4 5 6 7 8 9 10
week 24 11 12 13 14 15 16 17
week 25 18 19 20 21 22 23 24
week 26 25 26 27 28 29 30
Heike Pahl Profile Page
Heike Pahl


Lab: Prof. Dr. Heike Pahl
Department: Professor, Chair Section of Molecular Hematology
University Medical Center
Address: Breisacher Str. 66
79106 Freiburg
Phone: +49 761 270 63400
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Lab homepage:
PhD positions available: YES
Research Area: Molecular Medicine
Research Interests: -Molecular markers in Myeloproliferative Disorders
-The role of transcription factor NF-E2
-Molecular etiology of NF-E2 and PRV-1 Overexpression in MPD
-Molecular heterogeneity in Essential Thrombycythemia
-Mouse models of myeloproliferative disorders


Education & Training: 1985-1987: Wellesley College, Wellesley, MA, U. S. A. - Majors: Biochemistry and Economics
May 29, 1987: B.A., Wellesley College
1987-1992: Harvard University, Cambridge, MA, U. S. A.
June 7, 1990: M.A., Harvard University
July 14, 1992: Ph. D., Harvard University. Thesis: "Cloning and Characterization of the CD11b Promoter."
July 10, 1997: Habilitation at the Medical School of the Albert-Ludwigs-Universität Freiburg
Employment & Experience: 1992-1995: Postdoctoral Fellow at the Laboratory for Molecular Biology, Genecenter, of the Ludwig-Maximilians-Universität München and at the Institute for Biochemistry and Molecular Biology of the Albert-Ludwigs-Universität Freiburg in the laboratory of Prof. Dr. Patrick Baeuerle
1995-1997: Assistant Professor, Institute for Biochemistry and Molecular Biology of the Albert-Ludwigs-Universität
1998: Heisenberg-Stipend of the “Deutsche Forschungsgemeinschaft” (German equivalent of the NSF)
since 1998: Professor (tenured), University Medical Center of the Albert-Ludwigs-Universität Freiburg, Chair of the Section of Molecular Hematology
Scientific Activities: Editorial Board: Blood
Section Editor „Experimental Hematology“: Annals of Hematology
Editorial Board:Current Signal Transduction Therapy
Editorial Board: The European Journal of Clinical & Medical Oncology
Scientific Board: Else Kröner-Fresenius-Stiftung
Co-Organisation of the First International Workshop on Myeloproliferative Disorders: “Towards an Understanding of the Molecular Basis of Myeloproliferative Disorders”, Benediktiner Abtei, Frauenchiemsee, 23.-28. September 2000
Organisation of the Como Conference on Myeloproliferative Disorders. „The Molecular Pathogenesis and Genetics of Myeloproliferative Diseases” 13. - 17. Loveno di Menaggio, Italien, 13.-16. September 2002
Co-Organisation of the European School of Haematology Conferences: „Myeloproliferative Disorders: Molecular Pathogenesis and Therapy“, 2004, 2006, 2008, 2010, 2012, 2014


Honors and Awards:

1987 Phi Beta Kappa
1987 Sigma Xi
1991 Ryan Fellowship
1997 Preis "Best Oral Presentation" The Second European Meeting on Pathogenesis and Host Response in Helicobacter pylori  Infections
1997 Karl-Lohmann-Preis der Gesellschaft für Biochemie und Molekularbiologie
1998 Phoenix Pharmazie-Wissenschaftspreis
1998 Alfried Krupp-Förderpreis für Junge Hochschullehrer
1999 Sebastian Kneip-Preis
2000 Appointment to the „Junge Akademie“,founded by the Berlin-Brandenburgische Akademie der Wissenschaften and the Deutschen Akademie der Naturforscher Leopoldina
2000 Franziska Kolb-Preis for Research on Leukemia
2003 Forschungspreis der Leopoldina
2012 Berta Ottenstein Preis


Selected Publications:

Jutzi JS, Pahl HL (2015) The Hen or the Egg: Inflammatory Aspects of Murine MPN Models, Med. Inflamm. In press.

Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia, in press.

Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken J, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks, C, Wang W, Döhner K, Jansen JH, Pahl HL (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2, J. Ex. Med, 210: 1003 - 1019. Abstract

Aumann K, Frey AV, May AM, Hauschke D, Kreutz C, Marx JP, Timmer J, Werner M,  Pahl HL (2013) Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates pre-fibrotic primary myelofibrosis from essential thrombocythemia. Blood, 122: 93 - 99. Abstract

Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A , Pahl HL
(2013) Transcription factor NF-E2 mediates expression of the cytoine IL8, a known predictor of inferior outcome in MPN patients. Haematologica, 98: 1073 -1080. Abstract

Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayer S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL , (2012) Overexpression of transcription factor NF-E2: a novel murine model of myeloproliferative neoplasms. J. Exp. Med, 209 (1): 35 - 50. Abstract

Wang W, Schwemmers S, Hexner EO, Pahl HL (2010) AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. (2010) 116(2):254-66. Epub 2010 Mar 25. Abstract

Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Reiter A, Grand F, Cross NCP (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms, Nat Genet. (2009) 41(4):446-9. Epub 2009 Mar 15. Abstract

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL (2007) JAK2V617F-negative ET Patients do not display constitutively active JAK/STAT signaling. Exp. Hematol, 35: 1695 – 1703. Abstract

Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL (2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood, 106: 2862-2864. Abstract

SGBM PhD students

SGBM PhD students:

Track 1:
Jonas Jutzi (MD/PhD, since January 2015)



Track 1:
Ruzhica Bogeska (06/2008 - 05/2012)

Track 2:
Wei Wang (10/2005 - 08/2010)
Sven Schwemmers (09/2006 - 08/2010)

Copyright © 2009-2018 University of Freiburg